DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

Phase 2

Withdrawn

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Golimumab

First Posted Date: 2021-01-28

Last Posted Date: 2021-12-02

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT04729296

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Phase 2

Active, not recruiting

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8
Melanoma of Unknown Primary
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Recurrent Cutaneous Melanoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Procedure: Surgical Procedure
Drug: VLP-encapsulated TLR9 Agonist CMP-001

First Posted Date: 2021-01-14

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT04708418

Locations: 🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸
Centralia Oncology Clinic, Centralia, Illinois, United States
🇺🇸
Blanchard Valley Hospital, Findlay, Ohio, United States

and more 185 locations

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Phase 1

Active, not recruiting

Conditions: Oropharyngeal Cancer
Vaginal Cancer
Neck Cancer
Anal Cancer
Colon Cancer
Human Papillomavirus
Cervical Cancer
Vulvar Cancer
HPV
Penile Cancer

Interventions: Drug: Bintrafusp Alfa
Drug: PDS01ADC
Drug: Entinostat

First Posted Date: 2021-01-14

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT04708470

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Precision-Based Genomics in Prostate Cancer

Recruiting

Conditions: Prostate Cancer

First Posted Date: 2021-01-13

Last Posted Date: 2025-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2000

Registration Number: NCT04706663

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

and more 8 locations

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1

Recruiting

Conditions: Advanced Breast Carcinoma
Advanced Colon Carcinoma
Advanced Colorectal Carcinoma
Advanced Endometrial Carcinoma
Advanced Gastric Carcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Advanced Malignant Solid Neoplasm
Advanced Salivary Gland Carcinoma
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Ceralasertib
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Biological: Trastuzumab Deruxtecan

First Posted Date: 2021-01-12

Last Posted Date: 2025-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT04704661

Locations: 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 20 locations

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

Not Applicable

Recruiting

Conditions: Prostate Cancer

Interventions: Diagnostic Test: mpMRI

First Posted Date: 2021-01-05

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 508

Registration Number: NCT04692675

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Recruiting

Conditions: Primary Sclerosing Cholangitis

First Posted Date: 2020-12-28

Last Posted Date: 2025-05-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 143

Registration Number: NCT04685200

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01

Completed

Conditions: Familial Adenomatous Polyposis

Interventions: Other: Electronic Health Record Review

First Posted Date: 2020-12-19

Last Posted Date: 2022-06-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT04674228

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients

Completed

Conditions: Sleep Circadian Rhythms
Chronodisruption

First Posted Date: 2020-12-17

Last Posted Date: 2025-02-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 101

Registration Number: NCT04669574

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Recurrent Hypopharyngeal Squamous Cell Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Biological: Pembrolizumab
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Radiation: Proton Beam Radiation Therapy

First Posted Date: 2020-12-17

Last Posted Date: 2025-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 188

Registration Number: NCT04671667

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente-Anaheim, Anaheim, California, United States

and more 155 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy